menu
    • menu
    [{"orgOrder":0,"company":"Tetherex Pharmaceuticals","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetherex Pharmaceuticals Ink Licensing Deal with Mayo Clinic for Development of a Novel Single-Cycle Adenovirus Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Single-Cycle Adenovirus Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tetherex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tetherex Pharmaceuticals \/ Tetherex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Tetherex Pharmaceuticals \/ Tetherex Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Tetherex Pharmaceuticals

    Menu

    Tetherex Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tetherex Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Tetherex Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Single-Cycle Adenovirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Mayo Clinic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tetherex Pharmaceuticals Ink Licensing Deal with Mayo Clinic for Development of a Novel Single-Cycle Adenoviru...

                            Details : The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19. The Phase 1 open label study, designed to assess safety, reactogenicity and immunogenicity of the single-cycle...

                            Brand Name : SC-Ad6-1

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 06, 2021

                            Lead Product(s) : Single-Cycle Adenovirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Mayo Clinic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth